Levodopa-induced dyskinesia in Parkinson's disease: pathogenesis and emerging treatment strategies
The most commonly used treatment for Parkinson's disease (PD) is levodopa, prescribed in
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
conjunction with carbidopa. Virtually all patients with PD undergo dopamine replacement …
Sleep and circadian rhythms in Parkinson's disease and preclinical models
The use of animals as models of human physiology is, and has been for many years, an
indispensable tool for understanding the mechanisms of human disease. In Parkinson's …
indispensable tool for understanding the mechanisms of human disease. In Parkinson's …
[HTML][HTML] Lower urinary tract symptoms in depression: a review
DJ Anderson, A Aucoin, CR Toups… - Health psychology …, 2023 - ncbi.nlm.nih.gov
Abstract Lower Urinary Tract Symptoms (LUTS) are frequently present in the general
population as patients age with approximately a third of individuals experiencing LUTS …
population as patients age with approximately a third of individuals experiencing LUTS …
COMT Inhibitors in the Management of Parkinson's Disease
Levodopa treatment remains the gold standard for Parkinson's disease, but shortcomings
related to the pharmacological profile, notably, oral administration and the consequent …
related to the pharmacological profile, notably, oral administration and the consequent …
Revolutionizing our understanding of Parkinson's disease: Dr. Heinz Reichmann's pioneering research and future research direction
Millions of individuals around the world are afflicted with Parkinson's disease (PD), a
prevalent and incapacitating neurodegenerative disorder. Dr. Reichmann, a distinguished …
prevalent and incapacitating neurodegenerative disorder. Dr. Reichmann, a distinguished …
Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone
P Jenner, JF Rocha, JJ Ferreira, O Rascol… - Expert Review of …, 2021 - Taylor & Francis
Introduction Levodopa remains the gold-standard Parkinson's disease (PD) treatment, but
the inevitable development of motor complications has led to intense activity in pursuit of its …
the inevitable development of motor complications has led to intense activity in pursuit of its …
Newly approved and investigational drugs for motor symptom control in Parkinson's disease
DG Di Luca, NGD Reyes, SH Fox - Drugs, 2022 - Springer
Motor symptoms are a core feature of Parkinson's disease (PD) and cause a significant
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …
burden on patients' quality of life. Oral levodopa is still the most effective treatment, however …
Clinical benefit of MAO-B and COMT inhibition in Parkinson's disease: practical considerations
Inhibitors of monoamine oxidase B (MAO-B) and catechol-O-methyltransferase (COMT) are
major strategies to reduce levodopa degradation and thus to increase and prolong its effect …
major strategies to reduce levodopa degradation and thus to increase and prolong its effect …
Advances in the pharmacological and non-pharmacological management of non-motor symptoms in Parkinson's disease: an update since 2017
DJV Wamelen, K Rukavina… - Current …, 2023 - benthamdirect.com
Background: Non-motor symptoms (NMS) are an important and ubiquitous determinant of
quality of life in Parkinson's disease (PD). However, robust evidence for their treatment is still …
quality of life in Parkinson's disease (PD). However, robust evidence for their treatment is still …
What is the impact of catechol-O-methyltransferase (COMT) on Parkinson's disease treatment?
A Salamon, D Zádori, L Szpisjak… - Expert Opinion on …, 2022 - Taylor & Francis
Parkinson's disease (PD) is the second most common neurodegenerative disorder
worldwide [1]. From the pathological perspective, the etiology of the disease is the death of …
worldwide [1]. From the pathological perspective, the etiology of the disease is the death of …